olpadronic acid

Subscribe to Selected New Research on olpadronic acid

24 relevant articles (1 outcomes, 6 trials/studies) found for this Bio-Agent

Also Known As:

(3-dimethylamino-1-hydroxypropylidene)-1,1-biphosphonate; 3-dimethylamino-1-hydroxypropylidene-1,1-bisphosphonate; AHGA diphosphonate; Me2-APD; alpha-hydroxydimethyl-gamma-aminopropylidene biphosphonate; dimethyl-pamidronate; hydroxydimethyl aminopropylidene biphosphonate; olpadronate

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Organophosphorus Compounds: 126

Diphosphonates: 2715

olpadronic acid: 24

Experts

1.	Papapoulos, Socrates E: 3 articles (11/2003 - 04/2002)
2.	Hamdy, Neveen A T: 3 articles (11/2003 - 04/2002)
3.	Eekhoff, Marelise E M W: 2 articles (11/2003 - 05/2003)
4.	Zwinderman, Aeilko H: 2 articles (11/2003 - 04/2002)
5.	Cremers, Serge C L M: 2 articles (11/2003 - 05/2003)
6.	Janse, Arieke J: 1 article (11/2007)
7.	Pruijs, Hans E H: 1 article (11/2007)
8.	Verbout, Ab J: 1 article (11/2007)
9.	Castelein, Rene M: 1 article (11/2007)
10.	Kok, Dieke H J: 1 article (11/2007)

Related Diseases

1.	Osteitis Deformans (Paget's Disease of Bone) 11/01/2003 - "Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy." 05/01/2003 - "Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone." 12/01/1999 - "Short-term therapy with oral olpadronate in active Paget's disease of bone." 11/01/1995 - "Since the risk/benefit ratio of alendronate does not appear to be completely positive, it is likely that the future of treatment of Paget's disease of bone will be based on the oral formulation of the new bisphosphonates, including tiludronate, risedronate or dimethyl-pamidronate." Get all the results and reference details, order at left...
2.	Osteogenesis Imperfecta (Lobstein Disease) 05/01/2004 - "Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study." 11/01/2004 - "Olpadronate reduced fractures in children with osteogenesis imperfecta." 05/01/2004 - "INTERPRETATION: Oral treatment with olpadronate at a daily dose of 10 mg/m2 results in a reduction of fracture risk of long bones in children with osteogenesis imperfecta" 05/01/2004 - "METHODS: 34 children recruited from the Dutch national centre for osteogenesis imperfecta were randomly assigned olpadronate (10 mg/m2 daily; n=16) or placebo (n=18) for 2 years" 10/01/1997 - "Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate)." Get all the results and reference details, order at left...
3.	Osteoporosis 09/01/1998 - "The clinical efficacy demonstrated in preliminary studies in Paget's bone disease (including ultra-short treatments), and also in single-dose iv. therapy of hypercalcaemia of malignancies, renders olpadronate among the most promising bisphosphonate compounds, with potential use in the treatment of a variety of bone-involving diseases, such as osteoporosis, malignancies and rheumatoid arthritis." 07/01/1997 - "We studied 12 patients aged between 10.7 and 17.2 years with symptomatic osteoporosis and multiple fractures treated with the bisphosphonates pamidronate or olpadronate for periods between 2 and 8 years continuously" 11/04/2008 - "Bisphosphonates is a class of chemical compounds finding extensive medical applications against bone disorders including osteoporosis, Pagets' disease, etc. Non-N-containing members include etidronate, clodronate and tiludronate, while N-containing bisphosphonates include active pharmaceutical compounds such as pamidronate, neridronate, olpadronate, alendronate, ibandronate, risedronate and zoledronate" Get all the results and reference details, order at left...
4.	Metabolic Bone Diseases (Osteopenia) 01/01/1997 - "A safety margin of 200 to 300 : 1 between the "toxic" and "pharmacological" doses may be estimated if the total quantity of Olpadronate given to various animal species in toxicological studies and in pharmacodynamic experimental models (osteopenias due to estrogen deprivation or immobilization and retinoid-induced hypercalcemia) is considered" 11/01/2001 - "We compared similar doses of three different aminobisphosphonates (BP): olpadronate (OPD), pamidronate (APD), and alendronate (ALE) on osteopenia induced by thyroxine (T4)-treatment in OVX and SHAM adult rats" Get all the results and reference details, order at left...
5.	Bone Diseases (Bone Disease) 06/01/2005 - "Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease." 09/01/1998 - "The clinical efficacy demonstrated in preliminary studies in Paget's bone disease (including ultra-short treatments), and also in single-dose iv. therapy of hypercalcaemia of malignancies, renders olpadronate among the most promising bisphosphonate compounds, with potential use in the treatment of a variety of bone-involving diseases, such as osteoporosis, malignancies and rheumatoid arthritis." 09/01/1998 - "These features may explain the high tolerability reported after the administration of doses of olpadronate (by the oral route) up to 5- to 10-times higher than the maximum tolerated dose of alendronate in Paget's bone disease and bone metastases, thus widening the possibilities for its clinical usage" 06/01/2005 - "Thirty male adult Wistar rats (300-/+10 g body weight) underwent either 5/6 nephrectomy (Nx, n=20) or sham operation (SHAM, n=10) to determine olpadronate effects in an experimental model of uremic bone disease" Get all the results and reference details, order at left...
21 Diseases and 24 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Diphosphonates
2.	Interleukin 1 Receptor Antagonist Protein (Anakinra)
3.	Sirolimus (Rapamycin)
4.	Succinic Acid (Succinate)
5.	Teriparatide (Parathar)
6.	Lamivudine (3TC)
7.	Amlodipine (Norvasc)
8.	Citalopram (Escitalopram)
9.	Zidovudine (Retrovir)
10.	Yttrium
143 Drugs and Important Bio-Agents and 16 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Stents
2.	Nephrectomy
2 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>